Current surfactant use in premature infants

Area of Science:

• Neonatology
• Pulmonology
• Pediatric Critical Care

Background:

• Respiratory Distress Syndrome (RDS) is a common condition in preterm infants.
• Exogenous surfactant therapy has revolutionized RDS management.
• Both natural and synthetic surfactants are available, with natural surfactants showing advantages.

Purpose of the Study:

• To review the current evidence on exogenous surfactant therapy for RDS.
• To compare different surfactant administration strategies.
• To assess the safety and long-term outcomes of surfactant therapy.

Main Methods:

• Systematic review of clinical studies and trials.
• Meta-analysis of treatment outcomes, including mortality and morbidity.
• Evaluation of prophylactic versus rescue surfactant administration.
• Comparison of single versus multiple dosing strategies.

Main Results:

• Exogenous surfactant therapy significantly improves clinical outcomes and reduces mortality in preterm infants with RDS.
• Prophylactic surfactant administration is more beneficial than rescue therapy.
• Early treatment (before 2 hours) and multiple doses are superior to later treatment and single doses.
• Natural surfactants offer advantages over synthetic options.
• Adverse effects are infrequent and generally not serious.

Conclusions:

• Exogenous surfactant therapy is a cornerstone in managing preterm infants with RDS.
• Optimal use involves prophylactic or early administration of multiple doses, preferably natural surfactant.
• Long-term follow-up data are reassuring.
• Further research is needed to refine surfactant use with other respiratory interventions.